Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | HCK | P08631 | 2/20 | 0.61 |
| ▸ | ROS1 | P08922 | 2/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.61 |
| ▸ | FER | P16591 | 2/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | MARK3 | P27448 | 2/20 | 0.61 |
| ▸ | LTK | P29376 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.61 |
| ▸ | CLK2 | P49760 | 2/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.61 |
| ▸ | MAP3K10 | Q02779 | 2/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.61 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.61 |
| ▸ | STK3 | Q13188 | 2/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955335 | 0.85 | JAK2 (0.73) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14955477 | 0.84 | LCK (0.63) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14956736 | 0.83 | JAK2 (0.73) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14956161 | 0.82 | LRRK2 (0.61) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14955621 | 0.81 | SYK (0.72) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14955463 | 0.81 | SYK (0.72) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14956519 | 0.78 | LRRK2 (0.71) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14956521 | 0.78 | ALK (0.65) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14955574 | 0.78 | LRRK2 (0.56) | JAK2ROCK2MAP4K4HCKROS1 | |
| SCHEMBL14955998 | 0.77 | FER (0.72) | JAK2ROCK2MAP4K4HCKROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013078466-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | SYK, ZAP70, LCK | JAK2 29/4885ROCK2 411/4885MAP4K4 138/4885 |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | SYK, ZAP70, LCK | JAK2 29/4885ROCK2 411/4885MAP4K4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.